HPC releases preliminary CMIR on Dana‑Farber affiliation; staff flags market and access tradeoffs

The Health Policy Commission unanimously voted to release for public comment a preliminary cost‑and‑market‑impact review (CMIR) of a proposed clinical affiliation that would align Dana‑Farber Cancer Institute with Beth Israel affiliates and Harvard Medical Faculty Physicians and include construction of a new cancer hospital.

HPC staff described the proposal and process: Sasha haes rosnov led the presentation, explaining the affiliation would reassign medical‑oncology relationships so Dana‑Farber would be the preferred provider for certain inpatient medical‑oncology care, HMFP physicians would become Dana‑Farber employees, and the parties plan a new hospital with about 300 inpatient beds (including 30 beds moved from Dana‑Farber’s current license), observation capacity and new radiation units. The Department of Public Health is conducting a concurrent Determination of Need (DO) review and had published a staff report recommending approval with conditions; the DO process remains open and the HPC is a party of record in that process.

Modeling findings: HPC economists ran scenarios to estimate how patients might shift and what that would mean for spending and market structure. Staff estimated that shifting inpatient oncology volume to Dana‑Farber could lower commercial spending by roughly $8.5–$23 million annually in the modeled scenarios as Dana‑Farber’s current inpatient commercial prices are lower than some competitors. Conversely, staff warned that moving outpatient infusion and oncology drugs to Dana‑Farber pricing would raise commercial spending; staff presented model figures of approximately $26.5 million additional commercial drug spending and roughly $1.5 million for infusion services under certain assumptions. Staff also estimated Medicare spending impacts in the range of roughly $7.6–$9.1 million per year under current reimbursement assumptions, while noting uncertainty if repricing patterns changed in new settings.

Quality, access and workforce considerations: Staff concluded both parties are recognized high‑quality cancer providers and that party commitments could yield quality gains. At the same time, the review flagged short‑term risks from reconfiguring clinical teams and potential workforce competition for specialized oncology staff as Dana‑Farber scales a new facility; commissioners asked how the parties plan to build their workforce pipeline and whether that will draw staff from other providers. The CMIR also flagged the potential for further concentration of specialty cancer services in Boston and stressed access concerns for patients who face longer travel burdens.

Regulatory and next steps: Sasha explained that the HPC does not have authority to approve or deny the transaction but can influence market behavior through reporting and public comment. After release of the preliminary CMIR the submitting parties (Dana‑Farber and partners) will have an opportunity to respond; the HPC expects to issue a final CMIR in April. Staff said they would share the preliminary report with DPH staff as part of the concurrent DO review.

Commissioner reaction and vote: Commissioners asked technical and policy questions about Medicare reimbursement status (staff said Dana‑Farber appears likely to retain its current CMS payment status), the scale and necessity of new beds given uncertain future inpatient need, and whether some beds could be used flexibly for post‑acute care. Commissioner Cutler, an economist, said the analytical methods were appropriate; after discussion the commission voted to release the preliminary report for public comment and party response.

The HPC will accept party responses and public comment before finalizing the CMIR in April.